After completing this course, the reader will be able to: Describe the current role of ifosfamide in the treatment of soft tissue sarcomas in adult patients.Discuss factors that may affect ifosfamide metabolism and its therapeutic index.Explain the advantages of ifosfamide over doxorubicin in the context of new treatment combinations.Discuss strategies to improve survival outcome in patients with soft tissue sarcoma.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com
CITATION STYLE
Tascilar, M., Loos, W. J., Seynaeve, C., Verweij, J., & Sleijfer, S. (2007). The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas. The Oncologist, 12(11), 1351–1360. https://doi.org/10.1634/theoncologist.12-11-1351
Mendeley helps you to discover research relevant for your work.